Handelsavisen
prelaunch
Companies Healthcare 2666.HK
26
2666.HK HKEX Healthcare Facilities & Services

Genertec Universal Medical Group Co Ltd

HK$5,35
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
6,39 %
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Genertec Universal Medical Group Co Ltd operates in the healthcare facilities and services sector, providing medical services and related healthcare solutions.

Business. Genertec Universal Medical Group Co Ltd (2666.HK) is a healthcare services and equipment company primarily engaged in biotechnology activities within the healthcare facilities and services industry. The firm operates on a service-revenue model and is headquartered in China. It is listed on the Hong Kong Stock Exchange under the ticker symbol 2666.HK. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target6,90

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
6,90
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2666.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2666.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Genertec Universal Medical Group Co Ltd (2666.HK) is a healthcare services and equipment company primarily engaged in biotechnology activities within the healthcare facilities and services industry. The firm operates on a service-revenue model and is headquartered in China. It is listed on the Hong Kong Stock Exchange under the ticker symbol 2666.HK. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    Genertec Universal Medical Group Co Ltd has a basic and diluted share count of 2,014,204,924 shares outstanding, indicating no dilution from potential share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    Profitability and return metrics are not available for comparison against industry benchmarks, as the valuation snapshot does not provide relevant data. The company's performance in terms of return on invested capital (ROIC), operating margins, and other key profitability indicators remains unquantified.

    The company's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the risk associated with its segments or regions.

    The company's growth trajectory is not quantified in the available data, as no numeric deltas or revenue history are provided in the outlook. Analysts have provided a mean price target of 6.90 CNY, with a mean recommendation of 1.50 (1=strong buy, 5=strong sell), indicating a generally positive outlook.

    The company's risk assessment indicates low dilution risk, but liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents. No dilution sources are disclosed in the available data.

    Recent events, including filings and transcripts, are not disclosed in the available data, limiting the ability to assess the company's recent developments.

    Key takeaways
    • The company has no dilution from potential share issuance, with basic and diluted shares outstanding being equal.
    • Analysts have provided a positive outlook, with a mean price target of 6.90 CNY and a mean recommendation of 1.50.
    • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
    • Profitability and return metrics are not available for comparison against industry benchmarks.
    • The company's growth trajectory and revenue history are not quantified in the available data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2026-03-25
    FY 2026 · Full-year highlights

    Revenue ¥14.94B, +9,3% YoY; Operating income +5,7% YoY.

    Revenue¥14.94B+9,3 % YoY
    Operating income¥3.10B+5,7 % YoY
    Net income¥2.21B+5,0 % YoY
    Free cash flow¥1.50B+51,5 % YoY
    EPS
    Operating cash flow¥5.78B+407,4 % YoY
    Financials
    Income statement
    Revenue¥14.94B
    Gross profit¥5.03B
    Operating income¥3.10B
    Net income¥2.21B
    Margins
    Gross margin33.7%
    Operating margin20.7%
    Net margin14.8%
    FCF margin10.0%
    Balance sheet
    Total assets¥84.32B
    Total liabilities¥63.37B
    Total equity¥20.94B
    Cash & equivalents¥2.11B
    Long-term debt¥51.52B
    Cash flow
    Operating cash flow¥5.78B
    CapEx-¥988.9M
    Free cash flow¥1.50B
    SBC
    P&L flow · revenue → net income
    Revenue ¥14.94BOperating costs ¥11.84BTax ¥888.6MNet income ¥2.21B
    Highlights
    • Revenue ¥14.94B, +9,3% YoY
    • Operating income +5,7% YoY
    • Net income +5,0% YoY
    • Free cash flow +51,5% YoY
    • Net margin 14.8%

    Valuation FY

    Market price
    HK$5,35
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,15
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-19 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate1,12
    Revenueno estimateno estimate9,8B CNY
    Operating incomeno estimateno estimate3,1B CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy1
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price targetHK$6,80 · Median HK$6,80
    Low HK$6,80High HK$6,80
    Operating income · consensus3,1B CNY
    EPS surprise
    −3,4 %
    reported vs consensus · miss
    Revenue surprise
    +51,8 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowHK$6,90
    MeanHK$6,90
    MedianHK$6,90
    HighHK$6,90
    SpotHK$5,35
    +29.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Genertec Universal Medical Group Co Ltd Market data — financials · 2026-05-26
    • Genertec Universal Medical Group Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Leadership

    • Qi XiaChief Executive Officer, Executive Director
    • Shisu ChenExecutive Chairman of the Board
    • Wenbing WangChief Executive Officer, Executive Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2666.HKCanonical
    HKEX · HKD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-03-25 18:05 UTCEARNINGSAnnual results — FY 2026 Revenue CNY 14.94B · Net CNY 2.21B
    2025-03-26 09:32 UTCEARNINGSAnnual results — FY 2025 Revenue CNY 13.66B · Net CNY 2.10B
    2024-03-27 09:38 UTCEARNINGSAnnual results — FY 2024 Revenue CNY 13.65B · Net CNY 2.11B
    2023-03-29 09:32 UTCEARNINGSAnnual results — FY 2023 Revenue CNY 12.07B · Net CNY 1.96B
    2022-03-29 09:31 UTCEARNINGSAnnual results — FY 2022 Revenue CNY 9.91B · Net CNY 1.95B
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage